Dr M Senthilraja

PhD In Pharmaceutical Sciences

Drug design, New chemical entity, development of medicinal compounds, To develop drug .

RESEARCH PUBLICATIONS
1. Senthilraja. M. Application of Artificial Intelligence to Address Issues Related to Corono Virus, SLAS Technology Society for Laboratory Automation and Screening, 1(4), 2021, 1-4 (Impact Factor – 2.364) ISSN: 2472-6303 2472-6311 (web). .
2. Senthilraja. M, Amudhavalli.K, Vijayabaskaran.M, Sambathkumar .R. N-Benzyl-Amino Fumaramates: A Novel Class of Antibacterial and Antioxidants. World Journal of Pharmacy & Pharmaceutical Sciences, 2021, 10(8),1704-1712. SJIF Impact Factor 7.632. [DOI : 10.20959/wjpps20218-19537 ], ISSN 2278 – 4357.
3. Senthilraja. M. Role of Pharmacists in the Management and Prevention of Pneumonia in Adults, Journal of Bio Innovation, 2(1), 2021, 12-15.(Impact Factor- 4.396). Cross Ref Prefix: 10.46344/JBINO.
4. M. Senthilraja, A Chemical Rationale of Drug Stability and Degradation- An Insightful Approach, International Journal of Advanced Community Medicine, Accepted for September 2021 issue.
5. Senthilraja Manivannan, Design, Synthesis and Evaluation of Chalcones as anti-microbial agent, Indian Journal of Forensic and Community Medicine 2020; 7(3):120–123. Doi: .
6. Senthilraja. M, Reverse Phase High Performance Liquid Chromatography and UV-Visible method for the simultaneous estimation of Gemifloxacin, Indian Journal of Pharmacy and Pharmacology, 2019; 6(2): 60-64. (Impact Factor: 1.15).DOI 10.18231/j.ijpp.
7. Senthilraja

Principal Researcher of INDO-UKRAINE bilateral joint collaborative research project
from Department of Science & technology (DST), New Delhi, India with Danylo
Halytsky Lviv National Medical University, 79010, Lviv-10,Pekarska str, 69, Ukraine
from 2008 -2011.
Research group member of Danylo Halytsky Lviv National Medical University
Ukraine, 79010, Lviv-10, Pekarska str, 69.
Research group member of National University of Singapore, Singapore.
Research group member of Medicinal Chemistry Research Lab in MNR College of
Pharmacy, Sangaraddy, Telungana, India.

Principal Researcher of INDO-UKRAINE bilateral joint collaborative research project
from Department of Science & technology (DST), New Delhi, India with Danylo
Halytsky Lviv National Medical University, 79010, Lviv-10,Pekarska str, 69, Ukraine
from 2008 -2011.
Research group member of Danylo Halytsky Lviv National Medical University
Ukraine, 79010, Lviv-10, Pekarska str, 69.
Research group member of National University of Singapore, Singapore.
Research group member of Medicinal Chemistry Research Lab in MNR College of
Pharmacy, Sangaraddy, Telungana, India.

10 years

Branded Medicine Selling
Generic Medicine Selling
Pharma Franchise
Institutional Sales i.e. supply to hospitals, colleges, departments etc
Over the Counter (OTC) Drugs Sale
Supply to Pharmacy Chains
Supply to Online Pharmacy
Pharmaceutical Product’s Export
Pharmaceutical Product’s Import
Active Pharmaceutical Ingredients and other raw material trading business
Medical Devices and Surgical Dressing business

f the pharmaceutical industry is a national asset, we should enact public policies to protect and strengthen it. Therefore, those of us in industry, medicine, and universities need to demonstrate effectively the dynamics of drug discovery something we may not have been well equipped to do up to this point.

This effort will be helped by university scholars who are working to develop a model for analyzing pharmaceutical risk versus return, as well as other related subjects. In addition, studies are being conducted at Merck to complement university efforts. At a minimum, I would suggest that any economic model for the industry should consider four important issues:

1.
We must reexamine the way research is treated. Should it be a profit and loss (P&L) expense or amortized as an asset? The answer is important because it will change a number of financial measurements, most notably return on assets.

2.
Our analyses must consider pricing, including costs of research and launch prices fair to the patient and to the innovating company.

3.
We need an adequate period of exclusivity for innovative products.

4.
We need to factor in the impact of inflation on the cost of doing business and of future research.

Economic analyses are under way in four broad areas: industry dynamics, risk/return trade-offs, research productivity and innovation, and the regulatory environment.